Scientific Publications

Advancing dermatological science.

March 2024

AAD 2024

Pooled Efficacy, Patient-Reported Outcomes, and Safety of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Clinical Trials of Adults and Children With Atopic Dermatitis

March 2024

AAD 2024

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients 2 to 5 Years of Age with Mild to Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial

March 2024

AAD 2024

Roflumilast Foam 0.3% Once Daily in Patients With Seborrheic Dermatitis: Improvement in Patient-Reported Outcomes and Pruritus From a Phase 3 Trial (STRATUM)

October 2023

British Journal of Dermatology

Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study

May 2023

JAMA Dermatology

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial

March 2023

AAD 2023

Efficacy and Safety of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials

March 2023

AAD 2023

Patient and Healthcare Provider Perspectives on the Path to Diagnosis of Seborrheic Dermatitis: Results From a National Survey of Adults With Seborrheic Dermatitis in the United States

March 2023

AAD 2023

Patient and Healthcare Provider Perspective on the Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey

March 2023

AAD 2023

Patient and Healthcare Provider Perspective on the Treatment Patterns and Patient Satisfaction of Seborrheic Dermatitis in the United States: Results from a National Survey

March 2023

British Journal of Dermatology

Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial

November 2022

American Journal of Clinical Dermatology

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies

November 2022

American Journal of Clinical Dermatology

Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download